Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)
Hong Kong
· Delayed Price · Currency is HKD 3.650
-0.010 (-0.27%)
At close: Mar 10, 2026
HKG:2563 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 53.53 | 71.87 | 66.64 | 32.82 | 71.06 | - | Upgrade
|
| Revenue Growth (YoY) | 63.10% | 7.85% | 103.03% | -53.82% | - | - | Upgrade
|
| Cost of Revenue | 7.03 | 10.78 | 19.81 | 8.94 | 4.17 | - | Upgrade
|
| Gross Profit | 46.5 | 61.09 | 46.83 | 23.88 | 66.89 | - | Upgrade
|
| Selling, General & Admin | 90.68 | 114.27 | 139.3 | 149.41 | 267.37 | 39.35 | Upgrade
|
| Research & Development | 102.99 | 116.29 | 126.54 | 82.74 | 91.97 | 35.57 | Upgrade
|
| Other Operating Expenses | -0.46 | -1.66 | -1.25 | -15.25 | 0.96 | 0.8 | Upgrade
|
| Operating Expenses | 193.35 | 229.19 | 263.3 | 218.11 | 360.69 | 75.67 | Upgrade
|
| Operating Income | -146.85 | -168.1 | -216.47 | -194.23 | -293.79 | -75.67 | Upgrade
|
| Interest Expense | -0.04 | -0.06 | -0.06 | -0.07 | -0.07 | - | Upgrade
|
| Interest & Investment Income | 14.17 | 15.62 | 13.14 | 3.34 | 14.11 | 5.67 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.25 | 5.54 | 4.65 | 19.6 | -4.9 | -1.79 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.69 | - | - | - | -0.03 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | -129.78 | -146.99 | -198.74 | -171.36 | -284.68 | -71.8 | Upgrade
|
| Gain (Loss) on Sale of Investments | 2.54 | 3.22 | 9.1 | 10.85 | 8.46 | 2.04 | Upgrade
|
| Other Unusual Items | - | - | - | - | -1.92 | 4.51 | Upgrade
|
| Pretax Income | -127.26 | -143.78 | -189.64 | -160.51 | -278.14 | -65.25 | Upgrade
|
| Net Income | -127.26 | -143.78 | -189.64 | -160.51 | -278.14 | -65.25 | Upgrade
|
| Net Income to Common | -127.26 | -143.78 | -189.64 | -160.51 | -278.14 | -65.25 | Upgrade
|
| Shares Outstanding (Basic) | 360 | 352 | 350 | 350 | 350 | - | Upgrade
|
| Shares Outstanding (Diluted) | 360 | 352 | 350 | 350 | 350 | - | Upgrade
|
| Shares Change (YoY) | 2.79% | 0.71% | - | - | - | - | Upgrade
|
| EPS (Basic) | -0.35 | -0.41 | -0.54 | -0.46 | -0.79 | - | Upgrade
|
| EPS (Diluted) | -0.35 | -0.41 | -0.54 | -0.46 | -0.79 | - | Upgrade
|
| Free Cash Flow | -147.92 | -143.52 | -178.62 | -111.3 | -89.83 | -63.95 | Upgrade
|
| Free Cash Flow Per Share | -0.41 | -0.41 | -0.51 | -0.32 | -0.26 | - | Upgrade
|
| Gross Margin | 86.87% | 85.00% | 70.27% | 72.76% | 94.13% | - | Upgrade
|
| Operating Margin | -274.33% | -233.91% | -324.87% | -591.81% | -413.42% | - | Upgrade
|
| Profit Margin | -237.73% | -200.06% | -284.60% | -489.06% | -391.40% | - | Upgrade
|
| Free Cash Flow Margin | -276.33% | -199.71% | -268.05% | -339.12% | -126.41% | - | Upgrade
|
| EBITDA | -137.4 | -160.24 | -207.3 | -185.14 | -286.11 | -68.61 | Upgrade
|
| EBITDA Margin | -256.68% | -222.97% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 9.45 | 7.86 | 9.17 | 9.1 | 7.69 | 7.06 | Upgrade
|
| EBIT | -146.85 | -168.1 | -216.47 | -194.23 | -293.79 | -75.67 | Upgrade
|
| EBIT Margin | -274.33% | -233.91% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.